UNSPSC 51161725: Amiphenazole hydrochloride

This classification denotes a cns stimulant with the molecular formula C9H9N3S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W6W4748LIO, chemically known as 2,4-thiazolediamine, 5-phenyl- but more generally known as amiphenazole hydrochloride, which bears US NIH Compound Identifier 10275. European Medicines Agency schedules Amiphenazole hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00473MIG.

Most nations, for tariff and trade purposes, schedule amiphenazole hydrochloride under HS 29341000 and SITC 51579. As of Q4 2014, AMIPHENAZOLE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)C2C(NC(S2)N)N.CL.

UNSPSC 51161725 Amiphenazole hydrochloride is a Commodity code that in recent state and local procurement shows little direct activity under this specific pharmaceutical agent. The recent opportunities tagged to this code predominantly reflect broader pharmaceutical procurement — naloxone procurement, on-site pharmacy services, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical supply agreements — rather than solicitation for amiphenazole specifically. The issuing bodies span multiple jurisdiction types: county health departments (Seminole County, Florida; Hall County, Georgia), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and other participating jurisdictions). Pharmacy services and pharmaceutical supply represent the dominant transactional pattern, with vendors typically required to stock specified formularies, maintain supply chain security certifications (cGMP, DSCSA), and demonstrate cost competitiveness alongside technical qualifications.

Geographic activity is distributed across Florida, Georgia, Texas, Minnesota, and Oregon, with multistate cooperative purchasing vehicles extending reach across additional jurisdictions. Representative recent opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; Hall County's RFQ/P #47-010 (posted May 4, 2026, due June 4, 2026) for on-site pharmacy services at a county health clinic; and Minnesota's MMCAP RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers. The code shows minimal recent procurement specific to amiphenazole as a line item; vendors pursuing pharmaceutical opportunities under this code should focus on broader pharmaceutical supply, formulary management, and cost-competitive generic sourcing rather than single-agent procurement.